Prime Medicine Common Etf Analysis
| PRME Etf | USD 3.33 0.04 1.22% |
Prime Medicine Common holds a debt-to-equity ratio of 0.182. Prime Medicine's financial risk is the risk to Prime Medicine stockholders that is caused by an increase in debt.
Asset vs Debt
Equity vs Debt
Prime Medicine's liquidity is one of the most fundamental aspects of both its future profitability and its ability to meet different types of ongoing financial obligations. Prime Medicine's cash, liquid assets, total liabilities, and shareholder equity can be utilized to evaluate how much leverage the ETF is using to sustain its current operations. For traders, higher-leverage indicators usually imply a higher risk to shareholders. In addition, it helps Prime Etf's retail investors understand whether an upcoming fall or rise in the market will negatively affect Prime Medicine's stakeholders.
For many companies, including Prime Medicine, marketable securities, inventories, and receivables are the most common assets that could be converted to cash. However, for Prime Medicine Common, the most critical issue when managing liquidity is ensuring that current assets are properly aligned with current liabilities. If they are not, Prime Medicine's management will need to obtain alternative financing to ensure there are always enough cash equivalents on the balance sheet to meet obligations.
Price Book 3.6923 | Enterprise Value Ebitda (3.10) | Price Sales 99.3609 | Shares Float 104.3 M | Wall Street Target Price 6.4643 |
Given that Prime Medicine's debt-to-equity ratio measures a ETF's obligations relative to the value of its net assets, it is usually used by traders to estimate the extent to which Prime Medicine is acquiring new debt as a mechanism of leveraging its assets. A high debt-to-equity ratio is generally associated with increased risk, implying that it has been aggressive in financing its growth with debt. Another way to look at debt-to-equity ratios is to compare the overall debt load of Prime Medicine to its assets or equity, showing how much of the company assets belong to shareholders vs. creditors. If shareholders own more assets, Prime Medicine is said to be less leveraged. If creditors hold a majority of Prime Medicine's assets, the ETF is said to be highly leveraged.
Prime Medicine Common is undervalued with Real Value of 3.69 and Target Price of 6.46. The main objective of Prime Medicine etf analysis is to determine its intrinsic value, which is an estimate of what Prime Medicine Common is worth, separate from its market price. There are two main types of Prime Etf analysis: fundamental analysis and technical analysis.
The Prime Medicine etf is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Here, you can get updates on important government artifacts, including earning estimates, SEC corporate filings, announcements, and Prime Medicine's ongoing operational relationships across important fundamental and technical indicators.
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Prime Medicine Common. Also, note that the market value of any etf could be closely tied with the direction of predictive economic indicators such as signals in state. Prime Etf Analysis Notes
The fund maintains 99.55% of assets in stocks. Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address diseases by deploying gene editing technology. Prime Medicine is listed under Biotechnology in the United States and is traded on NASDAQ Exchange exchange. To find out more about Prime Medicine Common contact Keith MD at 617 465 0013 or learn more at https://primemedicine.com.Prime Medicine Common Investment Alerts
Many investors view ongoing market volatility as an opportunity to purchase more etfs at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Prime Medicine's investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Prime Medicine Common or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
| Prime Medicine generated a negative expected return over the last 90 days | |
| Prime Medicine has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 2.98 M. Net Loss for the year was (195.88 M) with loss before overhead, payroll, taxes, and interest of (154.05 M). | |
| Prime Medicine Common currently holds about 146.66 M in cash with (122.86 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 6.39, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 66.0% of the company shares are owned by institutional investors | |
| Latest headline from finance.yahoo.com: Jacob Funds Bets on Prime Medicine , a Next-Generation Gene Therapy Company | |
| The fund maintains 99.55% of its assets in stocks |
Prime Stock Institutional Investors
Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Geode Capital Management, Llc | 2025-06-30 | 1.5 M | State Street Corp | 2025-06-30 | 1.2 M | Greenwich Wealth Management Llc | 2025-06-30 | 846.2 K | Schonfeld Strategic Advisors Llc | 2025-06-30 | 818.5 K | Farallon Capital Management, L.l.c. | 2025-06-30 | 750 K | Morgan Stanley - Brokerage Accounts | 2025-06-30 | 587.7 K | Citadel Advisors Llc | 2025-06-30 | 521.5 K | Charles Schwab Investment Management Inc | 2025-06-30 | 518.6 K | Northern Trust Corp | 2025-06-30 | 512.2 K | Alphabet Inc | 2025-06-30 | 15.1 M | T. Rowe Price Investment Management,inc. | 2025-06-30 | 6.5 M |
Prime Market Capitalization
The company currently falls under 'Small-Cap' category with a current market capitalization of 593.88 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Prime Medicine's market, we take the total number of its shares issued and multiply it by Prime Medicine's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.Management Efficiency
Prime Medicine Common has return on total asset (ROA) of (0.3552) % which means that it has lost $0.3552 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.1234) %, meaning that it created substantial loss on money invested by shareholders. Prime Medicine's management efficiency ratios could be used to measure how well Prime Medicine manages its routine affairs as well as how well it operates its assets and liabilities.Prime Medicine Common has shown resilience through effective management strategies. Our analysis examines how these strategies influence financial outcomes and investor returns which helps in understanding the stock's long-term potential.
Top Prime Medicine Common Etf Constituents
| KRC | Kilroy Realty Corp | Stock | |
| AKR | Acadia Realty Trust | Stock | |
| HPP | Hudson Pacific Properties | Stock | |
| AVB | AvalonBay Communities | Stock | |
| BXP | Boston Properties | Stock | |
| EQIX | Equinix | Stock | |
| EQR | Equity Residential | Stock | |
| SPG | Simon Property Group | Stock | |
| FRT | Federal Realty Investment | Stock | |
| REXR | Rexford Industrial Realty | Stock | |
| PLD | Prologis | Stock | |
| ARE | Alexandria Real Estate | Stock | |
| VNO | Vornado Realty Trust | Stock | |
| ESS | Essex Property Trust | Stock | |
| MTSFF | Mitsui Fudosan Co | Pink Sheet |
Prime Medicine Common Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Prime Medicine insiders, such as employees or executives, is commonly permitted as long as it does not rely on Prime Medicine's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Prime Medicine insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Prime Medicine Outstanding Bonds
Prime Medicine issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Prime Medicine Common uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Prime bonds can be classified according to their maturity, which is the date when Prime Medicine Common has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| PRI 28 19 NOV 31 Corp BondUS74164MAB46 | View | |
| ADT Corp 4875 Corp BondUS74166NAA28 | View | |
| PRIME SEC SVCS Corp BondUS74166MAC01 | View | |
| PRIME SEC SVCS Corp BondUS74166MAF32 | View | |
| MPLX LP 4125 Corp BondUS55336VAK61 | View |
Prime Medicine Predictive Daily Indicators
Prime Medicine intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Prime Medicine etf daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Prime Medicine Forecast Models
Prime Medicine's time-series forecasting models are one of many Prime Medicine's etf analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Prime Medicine's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.Prime Medicine Common Debt to Cash Allocation
Many companies such as Prime Medicine, eventually find out that there is only so much market out there to be conquered, and adding the next product or service is only half as profitable per unit as their current endeavors. Eventually, the company will reach a point where cash flows are strong, and extra cash is available but not fully utilized. In this case, the company may start buying back its stock from the public or issue more dividends.
Prime Medicine Common currently holds 40.79 M in liabilities with Debt to Equity (D/E) ratio of 0.18, which may suggest the company is not taking enough advantage from borrowing. Prime Medicine Common has a current ratio of 6.57, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Prime Medicine until it has trouble settling it off, either with new capital or with free cash flow. So, Prime Medicine's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Prime Medicine Common sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Prime to invest in growth at high rates of return. When we think about Prime Medicine's use of debt, we should always consider it together with cash and equity.Prime Medicine Assets Financed by Debt
Typically, companies with high debt-to-asset ratios are said to be highly leveraged. The higher the ratio, the greater risk will be associated with the Prime Medicine's operation. In addition, a high debt-to-assets ratio may indicate a low borrowing capacity of Prime Medicine, which in turn will lower the firm's financial flexibility.Prime Medicine Corporate Bonds Issued
Most Prime bonds can be classified according to their maturity, which is the date when Prime Medicine Common has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
About Prime Etf Analysis
Etf analysis is the technique used by a trader or investor to examine and evaluate how Prime Medicine prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Prime shares will generate the highest return on investment. We also built our etf analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Etf such as Prime Medicine. By using and applying Prime Etf analysis, traders can create a robust methodology for identifying Prime entry and exit points for their positions.
Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address diseases by deploying gene editing technology. Prime Medicine is listed under Biotechnology in the United States and is traded on NASDAQ Exchange exchange.
Current Prime Analysis - Recommendations
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Prime analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Prime analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
| Target Price | Consensus | # of Analysts | |
| 6.46 | Strong Buy | 12 | Odds |
Most Prime analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Prime stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Prime Medicine Common, talking to its executives and customers, or listening to Prime conference calls.
Prime Etf Analysis Indicators
Prime Medicine Common etf analysis indicators help investors evaluate how Prime Medicine etf reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Prime Medicine shares will generate the highest return on investment. By understating and applying Prime Medicine etf analysis, traders can identify Prime Medicine position entry and exit signals to maximize returns.
| Begin Period Cash Flow | 55.1 M | |
| Total Stockholder Equity | 153.1 M | |
| Capital Lease Obligations | 40.8 M | |
| Property Plant And Equipment Net | 71.6 M | |
| Cash And Short Term Investments | 190.4 M | |
| Net Invested Capital | 153.1 M | |
| Cash | 182.5 M | |
| 50 Day M A | 3.8358 | |
| Net Interest Income | 3.5 M | |
| Total Current Liabilities | 38 M | |
| Investments | 68.5 M | |
| Stock Based Compensation | 26.1 M | |
| Common Stock Shares Outstanding | 118.6 M | |
| Total Cashflows From Investing Activities | 68.5 M | |
| Free Cash Flow | -130.2 M | |
| Other Current Assets | 21.4 M | |
| Accounts Payable | 11.4 M | |
| Net Debt | -141.7 M | |
| Other Operating Expenses | 205.4 M | |
| Non Current Assets Total | 85.6 M | |
| Liabilities And Stockholders Equity | 297.5 M | |
| Non Currrent Assets Other | 14.1 M |
Other Information on Investing in Prime Etf
Prime Medicine financial ratios help investors to determine whether Prime Etf is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Prime with respect to the benefits of owning Prime Medicine security.